Inqovi Approval History
FDA Approved: Yes (First approved July 7, 2020)
Brand name: Inqovi
Generic name: decitabine and cedazuridine
Dosage form: Tablets
Company: Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical
Treatment for: Myelodysplastic Syndrome
Inqovi (decitabine and cedazuridine) is a nucleoside metabolic inhibitor and cytidine deaminase inhibitor combination indicated for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).
- Inqovi is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
- Inqovi is taken orally once daily on Days 1 through 5 of each 28-day cycle. Tablets should be taken on an empty stomach.
- Common adverse reactions (incidence ≥ 20%) include fatigue, constipation, hemorrhage, myalgia, mucositis, arthralgia, nausea, dyspnea, diarrhea, rash, dizziness, febrile neutropenia, edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased.
Development History and FDA Approval Process for Inqovi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.